IN8bio (INAB) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Tvardi Therapeutics (TVRD) over the past year, losing 42.7% versus a loss of 97.3%. Over five years, INAB leads with a -99.2% price change compared with -99.8% for TVRD. Tvardi Therapeutics is the larger company by market cap ($13.9 million vs $13.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | TVRD |
|---|---|---|
| Share price | $1.35 | $1.04 |
| Market cap | $13.31M | $13.87M |
| 1-day change | -2.17% | -3.70% |
| YTD return | -41.03% | -74.88% |
| 1-year return | -42.74% | -97.29% |
| 5-year return | -99.23% | -99.77% |
| EPS (TTM) | $-1.62 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $43.65 |
| 52-week low | $0.88 | $0.93 |
| Distance from 52-week high | -50.55% | -97.62% |
| Analyst consensus | none | buy |
| Avg. price target upside | +418.52% | +789.42% |
| Average volume | 58.36K | 424.45K |
| Shares outstanding | 9.86M | 13.34M |
| Employees | 18 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed TVRD by 54.6 percentage points over the past year.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
INAB vs TVRD FAQ
Which is bigger, IN8bio or Tvardi Therapeutics?
Tvardi Therapeutics (TVRD) is larger, with a market capitalization of $13.87M compared with $13.31M for IN8bio (INAB).
Which stock has performed better over the past year, INAB or TVRD?
INAB returned -42.74% over the past 12 months, compared with -97.29% for TVRD (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Tvardi Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for IN8bio and Biotechnology: Pharmaceutical Preparations for Tvardi Therapeutics.